Axsome Therapeutics (AXSM) PT Set at $10.00 by HC Wainwright

HC Wainwright set a $10.00 price target on Axsome Therapeutics (NASDAQ:AXSM) in a research report report published on Tuesday. The firm currently has a buy rating on the stock.

Separately, Zacks Investment Research cut Axsome Therapeutics from a hold rating to a sell rating in a research note on Wednesday, September 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $11.38.

AXSM stock opened at $3.16 on Tuesday. The company has a current ratio of 2.26, a quick ratio of 2.26 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $90.57 million, a price-to-earnings ratio of -2.65 and a beta of -0.15. Axsome Therapeutics has a 1 year low of $2.05 and a 1 year high of $5.95.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Wednesday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.32). As a group, analysts predict that Axsome Therapeutics will post -1.15 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the business. Alethea Capital Management LLC lifted its stake in Axsome Therapeutics by 132.5% in the second quarter. Alethea Capital Management LLC now owns 270,823 shares of the company’s stock valued at $867,000 after buying an additional 154,323 shares during the last quarter. Sio Capital Management LLC bought a new stake in Axsome Therapeutics in the first quarter valued at $474,000. Finally, A.R.T. Advisors LLC bought a new stake in Axsome Therapeutics in the first quarter valued at $145,000. Institutional investors own 15.63% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.

Featured Story: Outstanding Shares and The Effect on Share Price

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply